Mizuho Issues Positive Forecast for Haemonetics (NYSE:HAE) Stock Price

Haemonetics (NYSE:HAE) had its target price hoisted by equities research analysts at Mizuho from $75.00 to $90.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the medical instruments supplier’s stock. Mizuho’s target price suggests a potential upside of 11.21% from the company’s current price.

A number of other analysts have also recently weighed in on the stock. Barrington Research increased their price target on shares of Haemonetics from $86.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Needham & Company LLC lowered Haemonetics from a “buy” rating to a “hold” rating in a report on Monday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Haemonetics in a research note on Monday, December 8th. CJS Securities upgraded Haemonetics to a “strong-buy” rating in a research note on Thursday, December 11th. Finally, Robert W. Baird boosted their target price on Haemonetics from $87.00 to $99.00 and gave the company an “outperform” rating in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.10.

Haemonetics Stock Performance

NYSE HAE opened at $80.93 on Wednesday. The company has a fifty day moving average of $66.63 and a two-hundred day moving average of $64.58. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03. Haemonetics has a 1 year low of $47.31 and a 1 year high of $87.32. The company has a market capitalization of $3.79 billion, a PE ratio of 23.66, a P/E/G ratio of 1.52 and a beta of 0.30.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. The firm had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The firm’s quarterly revenue was down 5.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, analysts expect that Haemonetics will post 4.55 earnings per share for the current year.

Institutional Investors Weigh In On Haemonetics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Parkside Financial Bank & Trust boosted its holdings in Haemonetics by 11.6% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,461 shares of the medical instruments supplier’s stock worth $109,000 after acquiring an additional 152 shares during the period. GAMMA Investing LLC lifted its position in shares of Haemonetics by 59.4% during the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 165 shares in the last quarter. Quarry LP grew its holdings in Haemonetics by 63.4% during the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 192 shares in the last quarter. Verdence Capital Advisors LLC grew its holdings in Haemonetics by 3.6% during the 2nd quarter. Verdence Capital Advisors LLC now owns 6,216 shares of the medical instruments supplier’s stock valued at $464,000 after purchasing an additional 214 shares in the last quarter. Finally, Retirement Systems of Alabama increased its stake in Haemonetics by 0.4% during the 2nd quarter. Retirement Systems of Alabama now owns 61,401 shares of the medical instruments supplier’s stock worth $4,581,000 after buying an additional 256 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.